Jun 28 2011
Jubilant Discovery Services Inc., Bedminster, New Jersey, a Jubilant Life Sciences Company, announced today that it has entered into a drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium, that will aim to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience.
Under the terms of the alliance agreement, Janssen will transfer ongoing efforts on selected drug discovery targets to Jubilant. Jubilant shall then carry out the research services and deliver preclinical candidates to Janssen for possible further development and commercialization. In addition to receiving research funding, Jubilant may also be eligible to receive milestones and royalties should Janssen successfully develop and commercialize the candidates.
Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant, said: "We are very pleased to collaborate with Janssen, a world leader in pharmaceutical research and commercialization. The collaboration will utilize Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centers. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."
Source:
JUBILANT DISCOVERY SERVICES INC.
New drug discovery platform aims to deliver first-in-class therapies